| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Glaxo Wellcome |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002084 |
Purpose
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.
| Condition | Intervention |
|
Herpes Simplex HIV Infections |
Drug: Valacyclovir hydrochloride Drug: Acyclovir |
| MedlinePlus related topics: | AIDS Herpes Simplex |
| ChemIDplus related topics: | Acyclovir Acyclovir sodium Valaciclovir Valacyclovir hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Safety Study |
| Official Title: | A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior conditions are excluded:
History of hypersensitivity to acyclovir.
Contacts and Locations |
Show 46 Study Locations |
| Glaxo Wellcome |
More Information
| Study ID Numbers: | 104B, 07 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002084 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
|
